{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:50:33Z","timestamp":1777881033482,"version":"3.51.4"},"reference-count":146,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medicine"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The increasing demand for precision medicine has spurred molecular diagnostic investigations to emphasize the utility of miRNA as significant biomarkers. Recent studies have underscored miRNA\u2019s role as prognostic, diagnostic, and therapeutic biomarkers in managing and monitoring multiple myeloma patients. This review aims to present the latest insights on the potential of circulating miRNA as prognostic, diagnostic, and therapeutic biomarkers in bortezomib-resistant multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>For this purpose, a comprehensive thematic literature review from January 2014 and August 2024 was conducted utilizing the databases CINAHL, Pubmed, and Google Scholar. Twenty pertinent studies were meticulously analyzed and categorized into the following sections: Bortezomib (BTZ) resistance in multiple myeloma, the predictive role of miRNAs in BTZ resistance, the impact of circulating miRNAs in multiple myeloma, and the potential of circulating miRNA as prognostic, diagnostic, and therapeutic biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of note, eight studies identified circulating miRNAs as diagnostic miRNA biomarkers (i.e., miR-744, miR-130a, let-7d, let-7e, miR-34a, etc.). In comparison, nine studies identified several circulating miRNAs that can be used as prognostic biomarkers (i.e., miR-20a, miR-483-5p, mir-1246, let-7a, let-7e, etc.). Moreover, five studies identified circulating miRNAs as promising therapeutic biomarkers (i.e., mir-15a, mir-92a, mir-19a, etc.). This discovery can significantly enhance early detection, accurate diagnosis, prognosis, overall survival rates, and quality of life for patients with multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Based on this evidence, exploring circulating miRNAs as a potential noninvasive biomarker for multiple myeloma represents a noteworthy advancement. This is attributed to the abundance of miRNAs in plasma or serum, which exhibits remarkable stability against enzymatic degradation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20503121251328486","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T03:22:37Z","timestamp":1745637757000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma"],"prefix":"10.1177","volume":"13","author":[{"given":"Shafisha","family":"Bamfield-Cummings","sequence":"first","affiliation":[{"name":"Department of Health Management, Economics, and Policy, Augusta University, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3368-3963","authenticated-orcid":false,"given":"Jeane","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Health Management, Economics, and Policy, Augusta University, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6001-2992","authenticated-orcid":false,"given":"Zubair A.","family":"Karim","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Dietetics, College of Allied Health Science, Augusta University, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_3_3_2","unstructured":"National Cancer Institute. Myeloma\u2014Cancer Stat Facts [Internet] SEER 2024 https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html(accessed 15 December 2024)."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742296"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02488-4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207651"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0410"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.12.026"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174249"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092569"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2352"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.200390"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123125"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111738"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2015.4"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0989-4"},{"key":"e_1_3_3_18_2","volume-title":"Bortezomib","author":"Sharma A","year":"2020","unstructured":"Sharma A, Preuss CV. Bortezomib. In: Treasure Island, FL: StatPearls Publishing, 2020."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2019.1632138"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010111"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02896-1"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157081"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071700"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.102"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2015-203414"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01601-1"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1210051"},{"issue":"2","key":"e_1_3_3_28_2","article-title":"Epigenetic regulation in cancer","volume":"5","author":"Gu M","year":"2024","unstructured":"Gu M, Ren B, Fang Y, et al. Epigenetic regulation in cancer. MedComm (2020) 2024; 5(2): e495.","journal-title":"MedComm (2020)"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112767"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.2217\/epi.15.57"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86473-y"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.08.016"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020336"},{"issue":"3","key":"e_1_3_3_34_2","first-page":"781","article-title":"[Application of miR-182 for determination of glucocorticoid-resistant patients with lymphoid malignancy]","volume":"25","author":"Hu YW","year":"2017","unstructured":"Hu YW, Chen SY, Xie YH. [Application of miR-182 for determination of glucocorticoid-resistant patients with lymphoid malignancy]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2017; 25(3): 781\u2013785.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S232388"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu10111618"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145002"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01457"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12251"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5144.5144"},{"issue":"1","key":"e_1_3_3_41_2","first-page":"33","article-title":"Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)","volume":"49","author":"Krishnan SR","unstructured":"Krishnan SR, Jaiswal R, Brown RD, et al. Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review). Int J Oncol 2016; 49(1): 33\u201350.","journal-title":"Int J Oncol 2016"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/brv.12170"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2015.1014802"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2019.1693543"},{"issue":"10","key":"e_1_3_3_45_2","first-page":"4483","article-title":"Progress and challenges of multi-drug resistance proteins in diseases","volume":"12","author":"Ding P","year":"2022","unstructured":"Ding P, Gao Y, Wang J, et al. Progress and challenges of multi-drug resistance proteins in diseases. Am J Cancer Res 2022; 12(10): 4483\u20134501.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-015-9757-1"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-3-732"},{"issue":"11","key":"e_1_3_3_48_2","first-page":"2709","article-title":"Efficacy of multi-drug resistance transporters and glutathione s-transferase P-1 at developing bortezomib resistance in multiple myeloma cell lines","volume":"40","author":"Kozalak G","year":"2021","unstructured":"Kozalak G, \u00d6ks\u00fczo\u011flu E. Efficacy of multi-drug resistance transporters and glutathione s-transferase P-1 at developing bortezomib resistance in multiple myeloma cell lines. Latin Am J Pharm 2021; 40(11): 2709\u20132716.","journal-title":"Latin Am J Pharm"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3390\/life12060897"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2016.09.002"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020149"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.891652"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201804161"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101429"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020407"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-021-00404-3"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02396-8"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188556"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05408-1"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104511"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1514-1"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167969"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268958"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227648"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2023.03.005"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708765"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12233"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes14071375"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01284"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna5020037"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698197"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.093500"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2015-1108"},{"issue":"3","key":"e_1_3_3_74_2","first-page":"4001","article-title":"The diagnostic and prognostic value of plasma microRNA\u2011125b\u20115p in patients with multiple myeloma","volume":"16","author":"Jiang Y","year":"2018","unstructured":"Jiang Y, Luan Y, Chang H, et al. The diagnostic and prognostic value of plasma microRNA\u2011125b\u20115p in patients with multiple myeloma. Oncol Lett 2018; 16(3): 4001\u20134007.","journal-title":"Oncol Lett"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2639"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23233"},{"issue":"1","key":"e_1_3_3_77_2","first-page":"847","article-title":"Circulating miR-448 acts as a potential diagnostic biomarker for multiple myeloma","volume":"27","author":"Chen D","year":"2022","unstructured":"Chen D, Chen T, Wang L, et al. Circulating miR-448 acts as a potential diagnostic biomarker for multiple myeloma. Hematology (Amsterdam, Netherlands) 2022; 27(1): 847\u2013852.","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2095890"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0219-x"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2015.06.006"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7319"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.05.010"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11040752"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04034-5"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29199"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9021"},{"issue":"2","key":"e_1_3_3_87_2","first-page":"1058","article-title":"MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2","volume":"43","author":"Tian F","year":"2019","unstructured":"Tian F, Zhan Y, Zhu W, et al. MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2. Int J Mol Med 2019; 43(2): 1058\u20131066.","journal-title":"Int J Mol Med"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2278431"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2377-4"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.608521"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.05.025"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2017.3999"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1059-5"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.47"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207539"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137294"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S270636"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5317"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12939"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.616711"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.3178"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-3225-y"},{"issue":"2","key":"e_1_3_3_103_2","first-page":"34","article-title":"miR-203 functions as a tumor suppressor by inhibiting epithelial to mesenchymal transition in ovarian cancer","volume":"7","author":"Zhao G","year":"2015","unstructured":"Zhao G, Guo Y, Chen Z, et al. miR-203 functions as a tumor suppressor by inhibiting epithelial to mesenchymal transition in ovarian cancer. J Cancer Sci Ther 2015; 7(2): 34\u201343.","journal-title":"J Cancer Sci Ther"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11626-016-0044-y"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-020-0161-3"},{"issue":"11","key":"e_1_3_3_106_2","first-page":"5979","article-title":"MiRNA-1246 suppresses the proliferation and migration of renal cell carcinoma through targeting CXCR4","volume":"24","author":"Liu H-T","year":"2020","unstructured":"Liu H-T, Fan W-X. MiRNA-1246 suppresses the proliferation and migration of renal cell carcinoma through targeting CXCR4. Eur Rev Med Pharmacol Sci 2020; 24(11): 5979\u20135987.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.06.059"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092415"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2017.00031"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16051033"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02226-9"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22175"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2020.4841"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1213827"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.29383"},{"key":"e_1_3_3_116_2","first-page":"148","article-title":"MicroRNA analysis for extramedullary multiple myeloma relapse","volume":"31","author":"Gregorov\u00e1 J","year":"2018","unstructured":"Gregorov\u00e1 J, Vr\u00e1bel D, Radov\u00e1 L, et al. MicroRNA analysis for extramedullary multiple myeloma relapse. Klin Onkol 2018; 31(Supplementum1): 148\u2013150.","journal-title":"Klin Onkol"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1219-0"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18739-3"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20198883"},{"issue":"2","key":"e_1_3_3_120_2","first-page":"466","article-title":"miR-143 inhibits migration and invasion through regulating LASP1 in human esophageal cancer","volume":"12","author":"Liu H","year":"2019","unstructured":"Liu H, Zheng M, Zhao Y, et al. miR-143 inhibits migration and invasion through regulating LASP1 in human esophageal cancer. Int J Clin Exp Pathol 2019; 12(2): 466\u2013476.","journal-title":"Int J Clin Exp Pathol"},{"issue":"23","key":"e_1_3_3_121_2","first-page":"10400","article-title":"LncRNA LOXL1-AS1 inhibited cell proliferation, migration and invasion as well as induced apoptosis in breast cancer via regulating miR-143-3p","volume":"23","author":"Li G-H","year":"2019","unstructured":"Li G-H, Yu J-H, Yang B, et al. LncRNA LOXL1-AS1 inhibited cell proliferation, migration and invasion as well as induced apoptosis in breast cancer via regulating miR-143-3p. Eur Rev Med Pharmacol Sci 2019; 23(23): 10400\u201310409.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2008-0"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2018.03.015"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0465-1"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32368"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmz141"},{"issue":"1","key":"e_1_3_3_127_2","first-page":"3750734","article-title":"Study on the potential mechanism of miR-22-5p in non-small-cell lung cancer","volume":"2022","author":"Han X","year":"2022","unstructured":"Han X, Li H, Liu S, et al. Study on the potential mechanism of miR-22-5p in non-small-cell lung cancer. Dis Mark 2022; 2022(1): 3750734.","journal-title":"Dis Mark"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444637"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5556"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2019.1652034"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.10828"},{"issue":"4","key":"e_1_3_3_132_2","first-page":"1439","article-title":"Elevation of miR-191-5p level and its potential signaling pathways in hepatocellular carcinoma: a study validated by microarray and in-house qRT-PCR with 1291 clinical samples","volume":"12","author":"Wu HY","year":"2019","unstructured":"Wu HY, Li MW, Li QQ, et al. Elevation of miR-191-5p level and its potential signaling pathways in hepatocellular carcinoma: a study validated by microarray and in-house qRT-PCR with 1291 clinical samples. Int J Clin Exp Pathol 2019; 12(4): 1439\u20131456.","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.594135"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3311-T"},{"issue":"12","key":"e_1_3_3_135_2","first-page":"7272","article-title":"MiRNA-130a-3p inhibits cell proliferation, migration, and TMZ resistance in glioblastoma by targeting Sp1","volume":"11","author":"Wang Z","year":"2019","unstructured":"Wang Z, Li Z, Fu Y, et al. MiRNA-130a-3p inhibits cell proliferation, migration, and TMZ resistance in glioblastoma by targeting Sp1. Am J Trans Res 2019; 11(12): 7272.","journal-title":"Am J Trans Res"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00626"},{"issue":"2","key":"e_1_3_3_137_2","first-page":"1646","article-title":"Let-7b acts as a tumor suppressor in osteosarcoma via targeting IGF1R","volume":"17","author":"Zhang K","year":"2019","unstructured":"Zhang K, Wang W, Liu Y, et al. Let-7b acts as a tumor suppressor in osteosarcoma via targeting IGF1R. Oncol Lett 2019; 17(2): 1646\u20131654.","journal-title":"Oncol Lett"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2021.01.008"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-568923"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1221"},{"issue":"3","key":"e_1_3_3_141_2","first-page":"1","article-title":"Bioinformatics approach: a powerful tool for microRNA research","volume":"11","author":"Rasheed Z.","year":"2017","unstructured":"Rasheed Z. Bioinformatics approach: a powerful tool for microRNA research. Int J Health Sci 2017; 11(3): 1\u20133.","journal-title":"Int J Health Sci"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.01330"},{"key":"e_1_3_3_143_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23395-2"},{"key":"e_1_3_3_144_2","article-title":"The reactome pathway knowledgebase","volume":"48","author":"Jassal B","year":"2019","unstructured":"Jassal B, Matthews L, Viteri G, et al. The reactome pathway knowledgebase. Nucleic Acids Res 2019; 48(D1): D498\u2013D503.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_3_145_2","article-title":"KEGG: biological systems database as a model of the real world","volume":"53","author":"Kanehisa M","year":"2024","unstructured":"Kanehisa M, Furumichi M, Sato Y, et al. KEGG: biological systems database as a model of the real world. Nucleic Acids Res 2024; 53(D1): D672\u2013D677.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky379"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02480-0"}],"container-title":["Sage Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121251328486","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20503121251328486","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121251328486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:30:13Z","timestamp":1777595413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20503121251328486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":146,"alternative-id":["10.1177\/20503121251328486"],"URL":"https:\/\/doi.org\/10.1177\/20503121251328486","relation":{},"ISSN":["2050-3121","2050-3121"],"issn-type":[{"value":"2050-3121","type":"print"},{"value":"2050-3121","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"article-number":"20503121251328486"}}